These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8665574)

  • 1. Intradermal administration of lipopolysaccharide in treatment of human cancer.
    Goto S; Sakai S; Kera J; Suma Y; Soma GI; Takeuchi S
    Cancer Immunol Immunother; 1996 May; 42(4):255-61. PubMed ID: 8665574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic analysis of high antitumor effect of intradermal administration of lipopolysaccharide from Pantoea Agglomerans.
    Iwamoto I; Goto S; Kera J; Soma G; Takeuchi S; Nagata Y
    Med Oncol; 1996 Jun; 13(2):103-9. PubMed ID: 9013473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor effect of lipopolysaccharide by intradermal administration as a novel drug delivery system.
    Inagawa H; Nishizawa T; Noguchi K; Minamimura M; Takagi K; Goto S; Soma G; Mizuno D
    Anticancer Res; 1997; 17(3C):2153-8. PubMed ID: 9216680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case report of far advanced gastric cancer with multiple liver metastasis (H3) treated with transarterial intermittent chemotherapy and intradermal administration of low molecular lipopolysaccharide (LPSp) extracted from Pantoea agglomerans].
    Kasugai H; Ishiyama J; Imai I; Fukuma E; Miyajima N; Kano N; Yamakawa T; Goto S; Kera J; Takeuchi S
    Gan To Kagaku Ryoho; 1995 Sep; 22(11):1690-3. PubMed ID: 7574794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions.
    Inagawa H; Nishizawa T; Honda T; Nakamoto T; Takagi K; Soma G
    Anticancer Res; 1998; 18(5D):3957-64. PubMed ID: 9854510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-finding study of nedaplatin and cyclophosphamide for patients with gynecological malignancies.
    Ito K; Adachi S; Itani Y; Koyama M; Hori K; Chin R; Shintani M; Beppu K; Kawai S; Saito K
    Jpn J Clin Oncol; 1999 Jun; 29(6):299-302. PubMed ID: 10418559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study of cyclophosphamide plus carboplatin in advanced ovarian carcinoma.
    Edmonson JH; McCormack GW; Krook JE; Long HJ; Jefferies JA; Richardson RL
    Cancer Treat Rep; 1987 Feb; 71(2):199-200. PubMed ID: 3542210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
    Valero V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin (JM 8), adriamycin and cyclophosphamide (JAC) in advanced ovarian carcinoma: a pilot study.
    Conte PF; Bruzzone M; Chiara S; Rosso R; Giaccone G; Carnino F; Guercio E; Ragni N; Foglia G; Bentivoglio G
    Tumori; 1988 Apr; 74(2):217-20. PubMed ID: 2453091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
    Lichtman SM; Ratain MJ; Van Echo DA; Rosner G; Egorin MJ; Budman DR; Vogelzang NJ; Norton L; Schilsky RL
    J Natl Cancer Inst; 1993 Aug; 85(16):1319-26. PubMed ID: 8340944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin.
    Edmonson JH; Hartmann LC; Long HJ; Colon-Otero G; Fitch TR; Jefferies JA; Braich TA; Maples WJ
    Cancer; 1992 Nov; 70(10):2529-39. PubMed ID: 1423182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of misonidazole (NSC#261037) plus cyclophosphamide in solid tumors.
    Davila E; Klein L; Vogel CL; Johnson R; Ostroy F; Browning S; Gorowski E; Furner RL; Presant CA
    J Clin Oncol; 1985 Jan; 3(1):121-7. PubMed ID: 3965629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer.
    Pagani O; Sessa C; Martinelli G; Cerny T; de Jong J; Goldhirsch A; Zimatore M; Cavalli F
    Ann Oncol; 1997 Jul; 8(7):655-61. PubMed ID: 9296218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer.
    Polyzos A; Tsavaris N; Kosmas C; Giannikos L; Katsikas M; Kalahanis N; Karatzas G; Christodoulou K; Giannakopoulos K; Stamatiadis D; Katsilambros N
    Oncology; 1999; 56(4):291-6. PubMed ID: 10343192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate Immunity Activated by Oral Administration of LPSp Is Phylogenetically Preserved and Developed in Broiler Chickens.
    Komori T; Saito K; Sawa N; Shibasaki Y; Kohchi C; Soma G; Inagawa H
    Anticancer Res; 2015 Aug; 35(8):4461-6. PubMed ID: 26168487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.